Diagnosis and Management of Neonatal Alloimmune Thrombocytopenia

Transfusion Medicine Reviews

Volumn 22, Issue 4, 2008, Pages 255-267

  Arnold, Donald M ^a,b   Smith, James W ^a,b   Kelton, John G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN; PREDNISONE; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN;

ACUTE KIDNEY FAILURE; ANTIBODY DETECTION; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE THROMBOCYTOPENIA; BRAIN HEMORRHAGE; BRONCHOSPASM; CESAREAN SECTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; FEVER; FLUID RETENTION; GENOTYPE; HEADACHE; HEART INFARCTION; HEMOLYSIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAUTERINE BLOOD TRANSFUSION; LARYNX EDEMA; MOOD DISORDER; NEWBORN; NEWBORN ALLOIMMUNE THROMBOCYTOPENIA; PARENT COUNSELING; PATHOPHYSIOLOGY; PHENOTYPE; PREGNANCY DIABETES MELLITUS; PRENATAL CARE; RADIOIMMUNOPRECIPITATION; SIDE EFFECT; STROKE; THORAX PAIN; THROMBOCYTE TRANSFUSION; TREATMENT PLANNING;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; ERYTHROBLASTOSIS, FETAL; HEMORRHAGE; HUMANS; INFANT, NEWBORN; LABORATORY TECHNIQUES AND PROCEDURES; MODELS, BIOLOGICAL; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 51449102370     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2008.05.003     Document Type: Article

References (89)

1. Kjeldsen-Kragh J., Killie M.K., Tomter G., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 110 (2007) 833-839
2. Williamson L.M., Hackett G., Rennie J., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 92 (1998) 2280-2287
3. Turner M.L., Bessos H., Fagge T., et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 45 (2005) 1945-1956
4. Uhrynowska M., Niznikowska-Marks M., and Zupanska B. Neonatal and maternal thrombocytopenia: Incidence and immune background. Eur J Haematol 64 (2000) 42-46
5. Burrows R.F., and Kelton J.G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 329 (1993) 1463-1466
6. Blanchette V.S., Johnson J., and Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin.Haematol 13 (2000) 365-390
7. Andrew M., and Kelton J. Neonatal thrombocytopenia. Clin Perinatol 11 (1984) 359-391
8. Hohlfeld P., Forestier F., Kaplan C., et al. Fetal thrombocytopenia: A retrospective survey of 5,194 fetal blood samplings. Blood 84 (1994) 1851-1856
9. Murphy M.F., Verjee S., and Greaves M. Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT). Br J Haematol 105 (1999) 123-126
10. Bussel J.B., Zacharoulis S., Kramer K., et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 45 (2005) 176-183
11. Mueller-Eckhardt C., Kiefel V., Grubert A., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1 (1989) 363-366
12. Spencer J.A., and Burrows R.F. Feto-maternal alloimmune thrombocytopenia: A literature review and statistical analysis. Aust N Z J Obstet Gynaecol 41 (2001) 45-55
13. Bonacossa I.A., and Jocelyn L.J. Alloimmune thrombocytopenia of the newborn: Neurodevelopmental sequelae. Am J Perinatol 13 (1996) 211-215
14. Bussel J.B., Zabusky M.R., Berkowitz R.L., et al. Fetal alloimmune thrombocytopenia. N Engl J Med 337 (1997) 22-26
15. Dale S.T., and Coleman L.T. Neonatal alloimmune thrombocytopenia: Antenatal and postnatal imaging findings in the pediatric brain. AJNR Am J Neuroradiol 23 (2002) 1457-1465
16. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: A prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group. Am J Perinatol 13 (1996) 423-431
17. Gruel Y., Boizard B., Daffos F., et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 68 (1986) 488-492
18. Castro Jr. C., Martinez E.D., Rodriguez R.C., et al. CNS siderosis and Dandy-Walker variant after neonatal alloimmune thrombocytopenia. Pediatr Neurol 32 (2005) 346-349
19. Vergani P., Strobelt N., Locatelli A., et al. Clinical significance of fetal intracranial hemorrhage. Am J Obstet Gynecol 175 (1996) 536-543
20. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 16 (2002) 69-72
21. Murphy M.F., and Bussel J.B. Advances in the management of alloimmune thrombocytopenia. Br J Haematol 136 (2007) 366-378
22. Kaplan C., Daffos F., Forestier F., et al. Management of alloimmune thrombocytopenia: Antenatal diagnosis and in utero transfusion of maternal platelets. Blood 72 (1988) 340-343
23. Radder C.M., Brand A., and Kanhai H.H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 84 (2003) 318-325
24. Glade-Bender J., McFarland J.G., Kaplan C., et al. Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr 138 (2001) 862-867
25. Jaegtvik S., Husebekk A., Aune B., et al. Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG. 107 (2000) 691-694
26. Killie M.K., Husebekk A., Kaplan C., et al. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: A retrospective study. Transfusion 47 (2007) 55-58
27. Maslanka K., Guz K., and Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia. Vox Sang 85 (2003) 326-327
28. Bessos H., Turner M., and Urbaniak S.J. Is there a relationship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia?. Immunohematol 21 (2005) 102-109
29. Ghevaert C., Campbell K., Walton J., et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 47 (2007) 901-910
30. Allen D., Rigsby P., Bessos H., et al. Collaborative study to establish the first international standard for quantitation of anti-HPA-1a. Vox Sang 89 (2005) 100-104
31. Bertrand G., Martageix C., Jallu V., et al. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 4 (2006) 628-637
32. Kaplan C. Fetal/neonatal allo-immune thrombocytopenias: the unsolved questions. Transfus Clin Biol 12 (2005) 131-134
33. Fratellanza G., Fratellanza A., Paesano L., et al. Fetoneonatal alloimmune thrombocytopenia (FNAIT): Our experience. Transfus Apher Sci 35 (2006) 111-117
34. Smith J.W., Kelton J.G., Horsewood P., et al. Platelet specific alloantigens on the platelet glycoprotein Ia/IIa complex. Br J Haematol 72 (1989) 534-538
35. Duncan J.R., and Rosse W.F. Alloantibody-induced platelet serotonin release is blocked by antibody to the platelet PLA1 antigen. Br J Haematol 64 (1986) 331-338
36. Furihata K., Nugent D.J., Bissonette A., et al. On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 80 (1987) 1624-1630
37. van Leeuwen E.F., Leeksma O.C., Van Mourik J.A., et al. Effect of the binding of anti-Zwa antibodies on platelet function. Vox Sang 47 (1984) 280-289
38. Burrows R.F., and Kelton J.G. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 319 (1988) 142-145
39. Porcelijn L., Folman C.C., de H.M., et al. Fetal and neonatal thrombopoietin levels in alloimmune thrombocytopenia. Pediatr Res 52 (2002) 105-108
40. Panzer S., Mayr W.R., and Eichelberger B. Light chain phenotypes of HLA antibodies in cases with suspected neonatal alloimmune thrombocytopenia. Vox Sang 89 (2005) 261-264
41. Thude H., Schorner U., Helfricht C., et al. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med 16 (2006) 143-149
42. Kelton J.G., Smith J.W., Horsewood P., et al. ABH antigens on human platelets: Expression on the glycosyl phosphatidylinositol-anchored protein CD109. J Lab Clin Med 132 (1998) 142-148
43. Ogasawara K., Ueki J., Takenaka M., et al. Study on the expression of ABH antigens on platelets. Blood 82 (1993) 993-999
44. Stockelberg D., Hou M., Rydberg L., et al. Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Transfus Med 6 (1996) 243-248
45. Curtis B.R., Fick A., Lochowicz A.J., et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 48 (2008) 358-364
46. von dem Borne A.E., and Decary F. Nomenclature of platelet-specific antigens. Hum Immunol 29 (1990) 1-2
47. Metcalfe P., Watkins N.A., Ouwehand W.H., et al. Nomenclature of human platelet antigens. Vox Sang 85 (2003) 240-245
48. Newman P.J., Derbes R.S., and Aster R.H. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 83 (1989) 1778-1781
49. Santoso S., Kiefel V., Richter I.G., et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta(3) integrin: The Oe(a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 99 (2002) 1205-1214
50. Davoren A., Curtis B.R., Aster R.H., et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 44 (2004) 1220-1225
51. Wang R., Furihata K., McFarland J.G., et al. An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system. J Clin Invest 90 (1992) 2038-2043
52. Berry J.E., Murphy C.M., Smith G.A., et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 110 (2000) 735-742
53. L'Abbe D., Tremblay L., Goldman M., et al. Alloimmunization to platelet antigen HPA-1a (Zwa): Association with HLA-DRw52a is not 100%. Transfus Med 2 (1992) 251
54. Valentin N., Vergracht A., Bignon J.D., et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 27 (1990) 73-79
55. Kaplan C., Porcelijn L., Vanlieferinghen P., et al. Anti-HPA-9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families. Transfusion 45 (2005) 1799-1803
56. Peterson J.A., Balthazor S.M., Curtis B.R., et al. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion 45 (2005) 1487-1495
57. Kelton J.G., Smith J.W., Horsewood P., et al. Gova/b alloantigen system on human platelets. Blood 75 (1990) 2172-2176
58. Smith J.W., Hayward C.P., Horsewood P., et al. Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. Blood 86 (1995) 2807-2814
59. Kjaer K.M., Jaegtvik S., Husebekk A., et al. Human platelet antigen 1 (HPA 1) genotyping with 5' nuclease assay and sequence-specific primers reveals a single nucleotide deletion in intron 2 of the HPA 1a allele of platelet glycoprotein IIIa. Br J Haematol 117 (2002) 405-408
60. Smith J.W., Hayward C.P., Warkentin T.E., et al. Investigation of human platelet alloantigens and glycoproteins using non-radioactive immunoprecipitation. J Immunol Methods 158 (1993) 77-85
61. Warner M.N., Moore J.C., Warkentin T.E., et al. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 104 (1999) 442-447
62. Bertrand G., Jallu V., Gouet M., et al. Quantification of human platelet antigen-1a antibodies with the monoclonal antibody immobilization of platelet antigens procedure. Transfusion 45 (2005) 1319-1323
63. Kiefel V., Santoso S., Weisheit M., et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 70 (1987) 1722-1726
64. Garner S.F., Smethurst P.A., Merieux Y., et al. A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a. Br J Haematol 108 (2000) 440-447
65. Denomme G.A., Waye J.S., Burrows R.F., et al. The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. Br J Haematol. 91 (1995) 742-746
66. Bussel J.B., Berkowitz R.L., McFarland J.G., et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med. 319 (1988) 1374-1378
67. Berkowitz R.L., Bussel J.B., and McFarland J.G. Alloimmune thrombocytopenia: State of the art 2006. Am J Obstet Gynecol 195 (2006) 907-913
68. Bussel J.B., Berkowitz R.L., Lynch L., et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: A randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 174 (1996) 1414-1423
69. Berkowitz R.L., Lesser M.L., McFarland J.G., et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: A randomized controlled trial. Obstet Gynecol 110 (2007) 249-255
70. Bussel J.B., Eldor A., Kelton J.G., et al. IGIV-C, a novel intravenous immunoglobulin: Evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 91 (2004) 771-778
71. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17 (2003) 241-251
72. Marie I., Maurey G., Herve F., et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 155 (2006) 714-721
73. Bussel J.B., McFarland J.G., and Berkowitz R.L. Antenatal management of fetal alloimmune and autoimmune thrombocytopenia. Transfus Med Rev 4 (1990) 149-162
74. Kaplan C., Murphy M.F., Kroll H., et al. Feto-maternal alloimmune thrombocytopenia: Antenatal therapy with IvIgG and steroids-More questions than answers. European Working Group on FMAIT. Br J Haematol 100 (1998) 62-65
75. Paidas M.J., Berkowitz R.L., Lynch L., et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 172 (1995) 475-479
76. Mackenzie F., Brennand J., Peterkin M., et al. Management of fetal alloimmune thrombocytopenia-A less invasive option?. J Obstet Gynaecol. 19 (1999) 119-121
77. Berkowitz R.L., Kolb E.A., McFarland J.G., et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 107 (2006) 91-96
78. van den Akker E.S., Oepkes D., Lopriore E., et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: Safe and effective. BJOG. 114 (2007) 469-473
79. Radder C.M., Brand A., and Kanhai H.H. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 185 (2001) 683-688
80. Yinon Y., Spira M., Solomon O., et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol. 195 (2006) 1153-1157
81. Letsky E.A., and Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. Br J Haematol. 95 (1996) 21-26
82. van den Akker E., Oepkes D., Brand A., et al. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?. BJOG 113 (2006) 781-783
83. Rayment R., Brunskill S.J., Stanworth S., et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev (2005) 1:CD004226
84. van den Akker E.S., and Oepkes D. Fetal and neonatal alloimmune thrombocytopenia. Best Pract Res Clin Obstet Gynaecol. 22 (2008) 3-14
85. Killie M.K., Kjeldsen-Kragh J., Husebekk A., et al. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 114 (2007) 588-595
86. Mueller-Eckhardt C., Kiefel V., and Grubert A. High-dose IgG treatment for neonatal alloimmune thrombocytopenia. Blut 59 (1989) 145-146
87. Allen D., Verjee S., Rees S., et al. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood 109 (2007) 388-389
88. Kiefel V., Bassler D., Kroll H., et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 107 (2006) 3761-3763
89. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 8 (2001) 249-254